Major Independent Trial Demonstrates Significant Anticancer Benefit Of Zometa(R) In Premenopausal Women With Early-Stage Breast Cancer

New data presented today showed that Zometa(R) (zoledronicacid) offered a significant anticancer benefit for premenopausal women withhormone-sensitive, early-stage breast cancer. The study found that Zometawhen added to hormone therapy, following surgery, significantly reduced therisk of cancer returning or death by 36% beyond clinical benefits achievedwith hormone therapy alone.

More: continued here

Filed under: Breast Cancer on June 1st, 2008